as.vestergaard99/100
Declared figure not adjusted upward between certificate and commercial documentation. Gradient and column chemistry stated.
KP — Zhuhai Kerui Biotechnology Co., Ltd.
Zhuhai, CN · established 2016. The index holds 223 assay reports across 40 batches and 24 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where KP sells
Zhuhai Kerui Biotechnology Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit KP at keruipeptides.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Zhuhai Kerui Biotechnology Co., Ltd.
- Short code in this index
- KP
- Also known as
- KP · KP Biotech · Zhuhai Kerui Biotechnology
- Domain
- keruipeptides.com →
- City
- Zhuhai
- Region
- Zhuhai
- Country
- CN
- Established
- 2016
- First record in index
- 26 Jun 2024
- Most recent record
- 13 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
13.5%
n=223
Retail, shipped to the buyer
70.4%
n=223
Direct to the laboratory
10.8%
n=223
Median courier leg, direct despatch
6d
n=24
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 30 | 13.5% |
| Retail purchase, shipped to the buyer | 134 | 60.1% |
| Retail purchase via a third-party forwarder | 23 | 10.3% |
| Supplier despatch direct to the laboratory | 24 | 10.8% |
| Laboratory retained-sample archive | 12 | 5.4% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 223 KP records the index holds, 30 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 16 of the 24 compounds KP is represented by here — Tirzepatide, Retatrutide, Semaglutide, IGF-1 LR3, Ipamorelin, N-Acetyl Semax Amide and 10 further compounds. Those are the KP lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents KP stock held in France, with a transit of 4 working days against a quoted 4. France is the only regional stock location named anywhere in KP's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is KP's own reviewers: 6 of the 26 on-record reviews state a quoted window and what happened against it. Where KP despatched a sample direct to a laboratory, the courier leg ran a median 6 days across 24 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.51%
n=223
Interquartile range
0.94pp
n=223
10th percentile
97.65%
n=223
Pass rate vs index spec
80.7%
n=223
Median recovery vs claim
97.9%
n=130
Median water
4.82%
n=223
Median |mass error|
2.5ppm
n=186
Records carrying a flag
16.1%
n=223
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.69pp
n=30
Index median spread
0.67pp
n=28
Lots tested 3+ times
30
n=40
Across the 30 KP lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.69 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=40
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
60%
n=40
Divergences beyond 1 pp
0%
n=40
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.44%
n=187
Supplier-supplied median
99.01%
n=24
Supplier-supplied share of records
10.8%
n=223
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of KP batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
74/100
n=40
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 57% | 25 points | |
| Peptide content stated | 50% | 20 points | |
| Endotoxin stated | 28% | 15 points | |
| Named impurities rather than a total | 34% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 40 | 98.10 | 98.55 | -0.45 | 97.0 | 100 |
| Semaglutide | Incretin | 29 | 98.31 | 98.89 | -0.58 | 97.0 | 100 |
| BPC-157 | Tissue-repair | 16 | 98.53 | 99.16 | -0.63 | 98.0 | 100 |
| Retatrutide | Incretin | 14 | 96.69 | 98.37 | -1.68 | 96.5 | 64 |
| Desmopressin | Hypothalamic | 12 | 98.66 | 98.83 | -0.17 | 98.5 | 67 |
| Semax | Neuroactive | 12 | 98.95 | 99.46 | -0.51 | 98.5 | 83 |
| 5-Amino-1MQ | Non-peptide | 11 | 99.58 | 99.45 | +0.13 | 98.0 | 100 |
| Melanotan II | Melanocortin-receptor | 9 | 98.09 | 99.42 | -1.33 | 98.5 | 0 |
| Ipamorelin | Growth-hormone | 8 | 99.14 | 99.47 | -0.33 | 99.0 | 75 |
| Sermorelin | Growth-hormone | 8 | 98.80 | 99.06 | -0.26 | 98.0 | 100 |
| TB-500 | Tissue-repair | 7 n=7 | 99.29 | 99.53 | -0.24 | 98.5 | 100 |
| Exenatide | Incretin | 7 n=7 | 98.18 | 98.98 | -0.80 | 98.0 | 71 |
| KPV | Tissue-repair | 7 n=7 | 99.16 | 99.64 | -0.48 | 99.0 | 71 |
| IGF-1 LR3 | Growth-hormone | 7 n=7 | 98.07 | 98.28 | -0.21 | 95.0 | 100 |
| Hexarelin | Growth-hormone | 6 n=6 | 98.69 | 99.59 | -0.90 | 99.0 | 17 |
| Epitalon | Short | 6 n=6 | 98.58 | 99.56 | -0.98 | 99.0 | 33 |
| CJC-1295 (no DAC) | Growth-hormone | 5 n=5 | 99.14 | 99.09 | +0.05 | 98.0 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 4 n=4 | 98.64 | 99.35 | -0.71 | 98.5 | 50 |
| GHRP-6 | Growth-hormone | 4 n=4 | 98.49 | 99.54 | -1.05 | 99.0 | 0 |
| Liraglutide | Incretin | 3 n=3 | 99.62 | 99.00 | +0.63 | 97.5 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 3 n=3 | 99.52 | 99.49 | +0.03 | 98.5 | 100 |
| CJC-1295 with DAC | Growth-hormone | 2 n=2 | n<3 | 98.95 | — | 97.5 | 100 |
| Selank | Neuroactive | 2 n=2 | n<3 | 99.59 | — | 99.0 | 0 |
| Pemvidutide | Incretin | 1 n=1 | n<3 | 98.25 | — | 96.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 1 | 2 | n<3 | 99.11–99.38 | 1 |
| 2024-Q3 | 5 | 33 | 98.01 | 96.98–99.93 | 4 |
| 2024-Q4 | 5 | 22 | 99.13 | 98.32–99.57 | 3 |
| 2025-Q1 | 3 | 10 | 98.80 | 98.30–99.67 | 7 |
| 2025-Q2 | 2 | 11 | 98.86 | 98.29–99.32 | 1 |
| 2025-Q3 | 4 | 23 | 98.26 | 97.80–99.93 | 5 |
| 2025-Q4 | 5 | 34 | 98.38 | 97.21–99.43 | 5 |
| 2026-Q1 | 5 | 21 | 98.39 | 96.75–99.73 | 4 |
| 2026-Q2 | 9 | 60 | 98.68 | 97.78–99.93 | 5 |
| 2026-Q3 | 1 | 7 | 96.46 | 95.81–96.64 | 1 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 97 | 98.51 | +0.00 | 98.51 |
| PeptideMeter | 38 | 98.40 | -0.05 | 98.45 |
| Medutest | 34 | 98.68 | +0.08 | 98.60 |
| VendorInvestigate | 22 | 98.22 | -0.11 | 98.33 |
| Nordanalyt | 14 | 98.59 | +0.02 | 98.58 |
| Kestrel | 18 | 99.31 | +0.24 | 99.07 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
92.0/ 100746 ratings across the index network
r.nwosu98/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Price quoted per milligram of declared peptide content rather than per vial, which is the only comparison that survives a content figure. Figures as reported by the named service. Not reproduced by the index.
a.okwuosa100/100
Quote returned with the correct vial size and the price held to invoice. Peptide content 98.6%.
d.antonsen92/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. n=1, declared as n=1.
a.lundgren100/100
Custom synthesis delivered inside the quoted schedule at the specified purity. Certificate carried the method in full.
c.asante99/100
Labelling printed, lot and date legible on every unit examined. Record covers the lots named. Not generalised.
am.frisk100/100
Phase-change pack solid at arrival, day 3. Documentation complete at first issue.
b.yilmaz97/100
Peptide content reported separately from chromatographic purity across all 4 certificates held. Quotation held from enquiry through to invoice with no revision and no added handling line.
i.aguirre96/100
Counter-ion identity and content answered quantitatively, one working day. Peptide content 98.0%.
n.jansen95/100
Direct-supply material 99.0%. Intermediary vial, same nominal description, 99.1%. Signature and release date present.
d.marchand100/100
Vials examined individually on receipt: flanges sound, crimps tight, cakes intact. Material returned 97.1%. Contributor declares no interest beyond the transaction.
a.varga99/100
Cold chain intact. Phase-change pack solid at arrival, day 2. Declared and independent figures differ by less than repeatability.
l.kowalski95/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Gradient and column chemistry stated.
z.nkemelu96/100
Consistency: 9 lots, purity band under 1.0 points wide.
m.lindholm98/100
Blind submission of DSIP 5 mg to Medutest, origin withheld. 98.6% against 98.7% declared. Documentation practice, not a single purity figure, is the substance here.
b.mensa99/100
Lot KP-25-323 submitted to PeptideMeter. Declared 98.0%, reported 98.2%. Delta inside method repeatability. Figures as reported by the named service. Not reproduced by the index.
lu.krastev95/100
Storage condition for the stability statement stated on the certificate. Evidence base adequate for a rating on this criterion.
f.okafor97/100
Transit 4 days from stock held in France against a quoted 4. Customs documentation correct at first presentation. Declared and independent figures differ by less than repeatability.
l.grimaldi99/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Desiccant enclosed within the secondary container. No adverse observation.
f.vermeulen95/100
Cross-check: Medutest and PeptideMeter, same lot, agreement to 0.1 points. Both agree with the declared figure. Identity confirmed by two orthogonal methods. Documentation practice, not a single purity figure, is the substance here.
k.castellanos96/100
Reconstitution of oxytocin 10 mg: clear on contact, no haze, no particulate. Peptide content 99.4%.
b.bhattacharya95/100
Water content by Karl Fischer, method named.
d.ogunleye98/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Research use. Not approved for human administration.
a.duarte97/100
Fill uniformity: 8 units weighed against declared fill, all within 2%. Declared and independent figures differ by less than repeatability. Further submissions on later lots would improve coverage.
m.halvorsen95/100
Repeat determination at 10 months: 97.0%. Original: 97.0%. No drift detected in this sample.
s.baptista99/100
Custom synthesis delivered 4 days inside the quoted schedule at the specified purity.
Block 12
Most recent records
Block 13
Contributor annotations on KP records 327
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on KP material are below, each linked to the record it sits on.
Deamidation is time, temperature and sequence. If the deamidated species is prominent here, the manufacture date on lot KP-2607-H5774 against the assay date above is the first arithmetic to do.
Incomplete deprotection leaves a +222 Da passenger that co-elutes late. If it is in the named table, the fix is a longer deprotection rather than a better purification.
Independently purchased, at the submitter's own cost, forwarded without the supplier's involvement. That is the definition and this record meets it.
Buyer-sourced through an ordinary retail order, so the supplier had no opportunity to select the vial. This is the provenance class the index weights and it is roughly 87 % of the dataset.
Integration on this trace is unambiguous: C18 diacid regioisomer at 1.77 % is baseline-resolved from the main peak, so 96.32 % is a measurement rather than a boundary decision.
Total peptide content and target-compound content are different numbers: the second is the first multiplied by purity. Certificates conflate them routinely and this record separates them.
Four slots — water, counter-ion, residual and peptide — are exhaustive and mutually exclusive. Anything that does not fit one of them is a fifth thing nobody measured, and on this record there is no remainder.
Where two laboratories tested the same retail lot, the paired difference is a clean estimate of inter-lab bias with no selection term in it at all. Those pairs are the backbone of the agreement analysis.
Every annotation the index holds on KP material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what KP itself publishes, open keruipeptides.com → alongside.
Block 14
Where to buy KP
Zhuhai Kerui Biotechnology Co., Ltd. sells direct from keruipeptides.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the KP store at keruipeptides.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.